免疫治疗在胃癌中的研究新进展
New Progress of Immunotherapy in Gastric Cancer
DOI: 10.12677/ACM.2023.133700, PDF,   
作者: 周星辰*：青海大学研究生院，青海 西宁；沈存芳#：青海大学附属医院肿瘤内科，青海 西宁
关键词: 胃癌；免疫治疗；PD-1抑制剂；过继细胞治疗；Gastric Cancer； Immunotherapy； PD-1 Inhibitor； Adoptive Cell Therapy
摘要: 胃癌是上消化道最常见的恶性肿瘤之一，早期胃癌患者经手术治疗有一定疗效，但胃癌的发生发展较为隐秘，大多数患者发现时已确诊为中期或中晚期，传统的治疗手段疗效仍不尽人意，近年来免疫治疗逐步登入世界的舞台，为中晚期胃癌患者的治疗模式提供了新的理念。相关研究表示，抗程序性死亡受体1 (PD-1)/程序性死亡配体1 (PD-L1)抗体等ICIs可以通过激活免疫反应有效地杀死癌细胞，ICIs的临床试验已经显示出对癌症患者的有效性和安全性。本文对胃癌患者免疫治疗的研究进展进行综述。
Abstract: Gastric cancer is one of the most common malignant tumors in the upper digestive tract. Patients with early gastric cancer have certain curative effects after surgical treatment, but the occurrence and development of gastric cancer is relatively secret. Most patients have been diagnosed as middle or late stage when they are found, and the curative effect of traditional treatment methods is still unsatisfactory. In recent years, immunotherapy has gradually entered the world stage, providing a new idea for the treatment mode of patients with middle and late stage gastric cancer. Relevant re-search shows that ICIs such as anti-programmed death receptor 1 (PD-1)/programmed death lig-and 1 (PD-L1) antibodies can effectively kill cancer cells by activating immune response. Clinical trials of ICIs have shown their effectiveness and safety for cancer patients. This article reviews the progress of immunotherapy for gastric cancer patients.
文章引用：周星辰, 沈存芳. 免疫治疗在胃癌中的研究新进展[J]. 临床医学进展, 2023, 13(3): 4904-4911. https://doi.org/10.12677/ACM.2023.133700

参考文献

[1] Song, Z., Wu, Y., Yang, J., Yang, D. and Fang, X. (2017) Progress in the Treatment of Advanced Gastric Cancer. Tu-mor Biology, 39, Article ID: 1393375038. [Google Scholar] [CrossRef] [PubMed]
[2] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[3] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[4] Chan, W.-L., Yuen, K.-K., Siu, S.W.-K., Lam, K.-O. and Kwong, D.L.-W. (2017) Third-Line Systemic Treatment Versus Best Supportive Care for Advanced/metastatic Gastric Cancer: A System-atic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology, 116, 68-81. [Google Scholar] [CrossRef] [PubMed]
[5] Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junc-tion, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. Lancet, 398, 27-40. [Google Scholar] [CrossRef] 
[6] Smyth, E.C., Nilsson, M., Grabsch, H.I., van Grieken, V.C. and Lordick, F. (2020) Gastric Cancer. Lancet, 396, 635-648. [Google Scholar] [CrossRef] 
[7] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 373, 23-34. [Google Scholar] [CrossRef] 
[8] Motzer, R.J., Escudier, B., McDermott, D.F., et al. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 373, 1803-1813. [Google Scholar] [CrossRef] 
[9] Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 375, 1823-1833. [Google Scholar] [CrossRef] 
[10] Jin, X., Liu, Z., Yang, D., Yin, K. and Chang, X. (2022) Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. Frontiers in Immunology, 13, Article 948647. [Google Scholar] [CrossRef] [PubMed]
[11] Kono, K., Nakajima, S. and Mimura, K. (2020) Current Status of Immune Checkpoint Inhibitors for Gastric Cancer. Gastric Cancer, 23, 565-578. [Google Scholar] [CrossRef] [PubMed]
[12] Muro, K., Chung, H.C., Shankaran, V., et al. (2016) Pembroli-zumab for Patients with PD-L1-Positive Advanced Gastric Cancer (KEYNOTE-012): A Multicentre, Open-Label, Phase 1b Trial. The Lancet Oncology, 17, 717-726. [Google Scholar] [CrossRef] 
[13] Kang, Y.-K., Boku, N., Satoh, T., et al. (2017) Nivolumab in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory To, or Intolerant Of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Place-bo-Controlled, Phase 3 Trial. Lancet, 390, 2461-2471. [Google Scholar] [CrossRef] 
[14] Janjigian, Y.Y., Kawazoe, A., Yañez, P., et al. (2021) The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric Cancer. Nature, 600, 727-730. [Google Scholar] [CrossRef] [PubMed]
[15] Takei, S., Kawazoe, A. and Shitara, K. (2022) The New Era of Immunotherapy in Gastric Cancer. Cancers, 14, Article No. 1054. [Google Scholar] [CrossRef] [PubMed]
[16] Wang, Q., Xie, Q., Liu, Y., et al. (2020) Clinical Characteristics and Prognostic Significance of TCGA and ACRG Classification in Gastric Cancer among the Chinese Population. Molecular Medicine Reports, 22, 828-840. [Google Scholar] [CrossRef] [PubMed]
[17] Kim, S.Y., Park, C., Kim, H.J., et al. (2015) Deregulation of Immune Response Genes in Patients with Epstein-Barr Virus-Associated Gastric Cancer and Outcomes. Gastroenterology, 148, 137-147. [Google Scholar] [CrossRef] [PubMed]
[18] The Cancer Genome Atlas Research Network (2014) Compre-hensive Molecular Characterization of Gastric Adenocarcinoma. Nature, 513, 202-209. [Google Scholar] [CrossRef] [PubMed]
[19] Xie, J., Fu, L. and Jin, L. (2021) Immunotherapy of Gastric Cancer: Past, Future Perspective and Challenges. Pathology-Research and Practice, 218, Article ID: 153322. [Google Scholar] [CrossRef] [PubMed]
[20] Bagheri, Y., Babaha, F., Falak, R., et al. (2019) IL-10 Induces TGF-β Secretion, TGF-β Receptor II Upregulation, and IgA Secretion in B Cells. European Cytokine Network, 30, 107-113.
[21] Wang, M., Busuttil, R.A., Pattison, S., et al. (2016) Immunological Battlefield in Gastric Cancer and Role of Immunotherapies. World Journal of Gastroenterology, 22, 6373-6384. [Google Scholar] [CrossRef] [PubMed]
[22] Tran, P.N., Sarkissian, S., Chao, J., and Klempner, S.J. (2017) PD-1 and PD-L1 as Emerging Therapeutic Targets in Gastric Cancer: Current Evidence. Gastrointestinal Cancer: Targets and Therapy, 7, 1-11. [Google Scholar] [CrossRef] 
[23] Helmy, K.Y., Patel, S.A., Nahas, G.R. and Rameshwar, P. (2013) Cancer Immunotherapy: Accomplishments to Date and Future Promise. Therapeutic Delivery, 4, 1307-1320. [Google Scholar] [CrossRef] [PubMed]
[24] Wang, J., Yuan, R., Song, W., et al. (2017) PD-1, PD-L1 (B7-H1) and Tu-mor-Site Immune Modulation Therapy: The Historical Perspective. Journal of Hematology & Oncology, 10, Article No. 34. [Google Scholar] [CrossRef] [PubMed]
[25] Li, B., Chan, H.L. and Chen, P. (2019) Immune Checkpoint In-hibitors: Basics and Challenges. Current Medicinal Chemistry, 26, 3009-3025. [Google Scholar] [CrossRef] [PubMed]
[26] Janjigian, Y.Y., Bendell, J., Calvo, E., et al. (2018) CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients with Metastatic Esophagogastric Cancer. Journal of Clinical Oncology, 36, 2836-2844. [Google Scholar] [CrossRef] 
[27] de Guillebon, E., Roussille, P., Frouin, E. and Tougeron D. (2015) Anti Program Death-1/Anti Program Death-Ligand 1 in Digestive Cancers. World Journal of Gastrointestinal Oncology, 7, 95-101. [Google Scholar] [CrossRef] [PubMed]
[28] Fuchs, C.S., Doi, T., Jang, R.W., et al. (2018) Safety and Ef-ficacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncology, 4, e180013. [Google Scholar] [CrossRef] [PubMed]
[29] Bang, Y.-J., Kang, Y.-K., Catenacci, D.V., et al. (2019) Pem-brolizumab Alone or in Combination with Chemotherapy as First-Line Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Results from the Phase II Nonrandomized KEYNOTE-059 Study. Gastric Cancer, 22, 828-837. [Google Scholar] [CrossRef] [PubMed]
[30] Davila, M.L., Bouhassira, D.C.G., Park, J.H., et al. (2014) Chi-meric Antigen Receptors for the Adoptive T Cell Therapy of Hematologic Malignancies. International Journal of Hema-tology, 99, 361-371. [Google Scholar] [CrossRef] [PubMed]
[31] Andre, T., Shiu, K.-K., Kim, T.W., et al. (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. New England Journal of Medicine, 383, 2207-2218. [Google Scholar] [CrossRef] 
[32] Sadelain, M., Rivière, I. and Brentjens, R. (2003) Targeting Tu-mours with Genetically Enhanced T Lymphocytes. Nature Reviews Cancer, 3, 35-45. [Google Scholar] [CrossRef] [PubMed]
[33] Slaney, C.Y., Kershaw, M.H. and Darcy, P.K. (2014) Trafficking of T Cells into Tumors. Cancer Research, 74, 7168-7174. [Google Scholar] [CrossRef] 
[34] Fournier, C., Martin, F., Zitvogel, L., et al. (2017) Trial Watch: Adoptively Transferred Cells for Anticancer Immunotherapy. Oncoimmunology, 6, e1363139. [Google Scholar] [CrossRef] 
[35] Zhang, H., Ye, Z.-L., Yuan, Z.-G., et al. (2016) New Strat-egies for the Treatment of Solid Tumors with CAR-T Cells. International Journal of Biological Sciences, 12, 718-729. [Google Scholar] [CrossRef] [PubMed]
[36] Vacchelli, E., Martins, I., Eggermont, A., et al. (2012) Trial Watch: Peptide Vaccines in Cancer Therapy. Oncoimmunology, 1, 1557-1576. [Google Scholar] [CrossRef] [PubMed]
[37] Matsueda, S. and Graham, D.Y. (2014) Immunotherapy in Gastric Cancer. World Journal of Gastroenterology, 20, 1657-1666. [Google Scholar] [CrossRef] [PubMed]
[38] Yang, J., Li, Z.H., Zhou, J.J., et al. (2010) Preparation and Antitumor Effects of Nanovaccines with MAGE-3 Peptides in Transplanted Gastric Cancer in Mice. Chinese Journal of Cancer, 29, 359-364. [Google Scholar] [CrossRef] [PubMed]
[39] Schwartzentruber, D.J., Lawson, D.H., Richards, J.M., et al. (2011) Gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma. New England Journal of Medicine, 364, 2119-2127. [Google Scholar] [CrossRef] 
[40] Okada, K., Fujiwara, Y., et al. (2013) Overexpression of Forkhead Box M1 Transcription Factor (FOXM1) Is a Potential Prognostic Marker and Enhances Chemoresistance for Docetaxel in Gastric Cancer. Annals of Surgical Oncology, 20, 1035-1043. [Google Scholar] [CrossRef] [PubMed]
[41] Higashihara, Y., Kato, J., Nagahara, A., et al. (2014) Phase I Clinical Trial of Peptide Vaccination with URLC10 and VEGFR1 Epitope Peptides in Patients with Advanced Gastric Cancer. International Journal of Oncology, 44, 662-668. [Google Scholar] [CrossRef] [PubMed]
[42] Ishikawa, H., Imano, M., Shiraishi, O., et al. (2014) Phase I Clinical Trial of Vaccination with LY6K-Derived Peptide in Patients with Advanced Gastric Cancer. Gastric Cancer, 17, 173-180. [Google Scholar] [CrossRef] [PubMed]
[43] Masuzawa, T., Fujiwara, Y., Okada, K., et al. (2012) Phase I/II Study of S-1 plus Cisplatin Combined with Peptide Vaccines for Human Vascular Endothelial Growth Factor Receptor 1 and 2 in Patients with Advanced Gastric Cancer. International Journal of Oncology, 41, 1297-1304. [Google Scholar] [CrossRef] [PubMed]
[44] Fujiwara, Y., Okada, K., Omori, T., et al. (2017) Multiple Therapeutic Peptide Vaccines for Patients with Advanced Gastric Cancer. International Journal of Oncology, 50, 1655-1662. [Google Scholar] [CrossRef] [PubMed]

为你推荐